Guardian Pharmacy Services (GRDN) Q3 2026 earnings summary

Executive summary

• Q3 revenue was $371.1M, down 1.7% YoY amid IRA-related pricing reductions; net income was $19.1M and Adjusted EBITDA rose 24% to $33.9M.

• Served 218,000 residents, up 7% YoY; prescription volume rose 10%, supporting higher profitability.

• FY 2026 revenue guidance increased to $1.44B–$1.46B and Adjusted EBITDA guidance to $136M–$138M.

Financial highlights

• Q3 gross profit rose to $85.2M from $74.7M; operating income increased to $25.1M from $16.4M.

• Q3 diluted EPS was $0.29 vs. $0.15; Adjusted EPS was $0.33 vs. $0.25.

• 9M revenue was $1.059B vs. $1.051B; net income was $54.8M vs. $27.7M, including an $8.5M payor settlement received in 2026.

• 9M Adjusted EBITDA was $93.3M vs. $75.7M; Adjusted EPS was $0.91 vs. $0.69.

Outlook and guidance

• FY 2026 revenue guidance rose from $1.43B–$1.45B to $1.44B–$1.46B; Adjusted EBITDA guidance rose from $129M–$131M to $136M–$138M.

• Updated outlook reflects Q3 outperformance, market expansion and improved reimbursement and operating trends; excludes future acquisitions.

• IRA-related drug price reductions are expected to weigh on YoY comparisons through the remainder of 2026.

• Cash, expected operating cash flows and available credit were viewed as sufficient for working capital and capital expenditures for at least 12 months.